TY - JOUR
T1 - Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF
AU - Atiq, Ferdows
AU - Blok, Robin
AU - van Kwawegen, Calvin B.
AU - Hulshof, Anne Marije
AU - Doherty, Dearbhla
AU - Lavin, Michelle
AU - van der Bom, Johanna G.
AU - O'Connell, Niamh M.
AU - de Meris, Joke
AU - Ryan, Kevin
AU - Schols, Saskia E.M.
AU - van Heerde, Waander L.
AU - Doyle, Mairead
AU - Byrne, Mary
AU - Heubel-Moenen, Floor C.J.I.
AU - van Galen, Karin P.M.
AU - Preston, Roger J.S.
AU - Cnossen, Marjon H.
AU - Fijnvandraat, Karin
AU - Baker, Ross I.
AU - Meijer, Karina
AU - James, Paula
AU - Di Paola, Jorge
AU - Eikenboom, Jeroen
AU - Leebeek, Frank W.G.
AU - O'Donnell, James S.
N1 - Publisher Copyright:
© 2025 American Society of Hematology
PY - 2025/7/17
Y1 - 2025/7/17
N2 - Previous reports have highlighted that some patients with low von Willebrand factor (VWF) with significant bleeding were diagnosed based on an isolated but persistent reduction in plasma VWF activity levels in the 30 to 50 IU/dL range. These patients had plasma VWF antigen (VWF:Ag) levels >50 IU/dL and thus had qualitative low VWF (low VWF–QL) rather than quantitative low VWF. Although the clinical importance of functional VWF defects in type 2 von Willebrand disease (VWD) is well recognized, the translational implications of mild functional defects in patients with low VWF–QL have not been defined. To address this clinically important question, we combined low VWF data sets from the low VWF in Ireland cohort and the low VWF in Erasmus MC studies. Overall, we observed that low VWF–QL was common and accounted for ∼50% of our combined low VWF cohort. Importantly, our findings demonstrated that many of these patients with mild isolated functional VWF defects in the 30 to 50 IU/dL range had significant bleeding phenotypes, although their plasma VWF:Ag levels were within the normal range. In addition, we further showed that low VWF–QL is a distinct clinicopathological entity compared to type 2 VWD. Finally, our studies highlighted that low VWF–QL is predominantly caused by abnormalities in VWF biosynthesis within endothelial cells that are occurring largely independent of identifiable pathological VWF sequence variants. Cumulatively, these novel observations have important clinical implications for the diagnosis and management of patients with mild functional VWF defects.
AB - Previous reports have highlighted that some patients with low von Willebrand factor (VWF) with significant bleeding were diagnosed based on an isolated but persistent reduction in plasma VWF activity levels in the 30 to 50 IU/dL range. These patients had plasma VWF antigen (VWF:Ag) levels >50 IU/dL and thus had qualitative low VWF (low VWF–QL) rather than quantitative low VWF. Although the clinical importance of functional VWF defects in type 2 von Willebrand disease (VWD) is well recognized, the translational implications of mild functional defects in patients with low VWF–QL have not been defined. To address this clinically important question, we combined low VWF data sets from the low VWF in Ireland cohort and the low VWF in Erasmus MC studies. Overall, we observed that low VWF–QL was common and accounted for ∼50% of our combined low VWF cohort. Importantly, our findings demonstrated that many of these patients with mild isolated functional VWF defects in the 30 to 50 IU/dL range had significant bleeding phenotypes, although their plasma VWF:Ag levels were within the normal range. In addition, we further showed that low VWF–QL is a distinct clinicopathological entity compared to type 2 VWD. Finally, our studies highlighted that low VWF–QL is predominantly caused by abnormalities in VWF biosynthesis within endothelial cells that are occurring largely independent of identifiable pathological VWF sequence variants. Cumulatively, these novel observations have important clinical implications for the diagnosis and management of patients with mild functional VWF defects.
UR - https://www.scopus.com/pages/publications/105005515507
U2 - 10.1182/blood.2024028035
DO - 10.1182/blood.2024028035
M3 - Article
C2 - 40279514
AN - SCOPUS:105005515507
SN - 0006-4971
VL - 146
SP - 369
EP - 381
JO - Blood
JF - Blood
IS - 3
ER -